Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cytokine-Immunotherapy for Low-Risk MDS
NCT00520468Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2004
- Primary completion
- Jun 2009
- Modality
- Orthosteric Ligands, Cytokines & Interferons, Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of erythropoietin, filgrastim, prednisone, cyclosporine in myelodysplastic syndrome (MDS), sponsored by University of Texas MD Anderson Cancer Center. Started Jun 2004; status: completed.
02
Drugs
erythropoietinfilgrastimprednisonecyclosporine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00520468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00520468.